The accessibility of innovative drugs is a common challenge for the medical and healthcare system around the world. Presently，China has achieved the payment management of innovative drugs through the periodic negotiation of accessing a catalog of medicines covered by the national medical insurance system. Some of the innovative drugs that have included in the catalog of medicines covered by national health insurance are difficult to be admitted to hospitals，which results in a problem that the policy of health insurance negotiation and other related policies are not benefited all people. Based on the positioning of national medical insurance inclusion of innovative drugs，social and economic development，and the reality of the medical insurance system in China，this paper analyzes the objective reasons for the hinder of “admission” of innovative drugs to hospitals and gives relevant suggestions for optimizing the accessibility of innovative drugs.